1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Feb 2020
Admin
News Article

Usfda Issues 2 Observations After Inspection Of Lupin'S Pithampur Unit

Drug Firm Lupin On Wednesday Said The Us Health Regulator Has Issued Two Observations After Inspection Of The Company'S Madhya Pradesh Facility.The Inspection Of The Company'S Pithampur Unit-I Facility By The United States Food And Drug Administration (Usfda) Has Been Completed, Lupin Said In A Filing To Bse.The Inspection, Carried Out Between February 3 And February 11, 2020, Closed With Two 483 Observations, It Added.An Fda Form 483 Is Issued To A Firm Management At The Conclusion Of An Inspection When An Investigator(S) Has Observed Any Conditions That In Their Judgment May Constitute Violations Of The Food Drug And Cosmetic Act And Related Acts.It Notifies The Company'S Management Of Objectionable Conditions At The Facility."We Uphold The Highest Standards Of Quality And Compliance Across Our Manufacturing Operations And Are Committed To Consistently Produce And Distribute Products Of The Highest Quality," Lupin Md Nilesh Gupta Said.Shares Of Lupin Closed At Rs 702.35 Per Scrip On Bse, Down 0.36 Per Cent From The Previous Close.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!